Coherus Oncology (CHRS) Retained Earnings (2013 - 2026)
Coherus Oncology's (CHRS) quarterly Retained Earnings came in at -$1.4 billion in Q1 2026, up 11.59% year-on-year from -$1.3 billion in Q1 2025, and down 728769.74% quarter-over-quarter from -$195000.0 in Q4 2025.
Coherus Oncology (CHRS) Retained Earnings (2013 - 2026) Analysis & Trends
Coherus Oncology has disclosed Retained Earnings across 14 years of filings, most recently posting -$1.4 billion for Q1 2026.
- Retained Earnings for Q1 2026 came in at -$1.4 billion, up 11.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 billion (up 11.59% YoY), and the FY2025 annual result was -$195000.0, up 29.09% from the prior year.
- Retained Earnings came in at -$1.4 billion for Q1 2026 at Coherus Oncology, down from -$195000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$195000.0 in Q4 2025 to a low of -$1.6 billion in Q1 2025.
- The 5-year median for Retained Earnings is -$275000.0 (2024), against an average of -$590.2 million.
- Across the five-year window, Retained Earnings soared 99.98% in 2024 and slumped 590915.44% in 2025, its largest moves.
- Coherus Oncology's Retained Earnings stood at -$1.3 billion in 2022, then soared by 99.98% to -$248000.0 in 2023, then decreased by 10.89% to -$275000.0 in 2024, then grew by 29.09% to -$195000.0 in 2025, then plunged by 728769.74% to -$1.4 billion in 2026.
- The last three Retained Earnings figures came in at -$1.4 billion (Q1 2026), -$195000.0 (Q4 2025), and -$203000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Coherus Oncology | 199.14 Mn | 32.09 Mn | 8.50 Mn | -1.42 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.42 Bn |
| Dec 31, 2025 | -195,000.00 |
| Sep 30, 2025 | -203,000.00 |
| Jun 30, 2025 | -275,000.00 |
| Mar 31, 2025 | -1.61 Bn |
| Dec 31, 2024 | -275,000.00 |
| Sep 30, 2024 | -275,000.00 |
| Jun 30, 2024 | -272,000.00 |
| Mar 31, 2024 | -272,000.00 |
| Dec 31, 2023 | -248,000.00 |
| Sep 30, 2023 | -1.50 Bn |
| Jun 30, 2023 | -1.46 Bn |
| Mar 31, 2023 | -1.42 Bn |
| Dec 31, 2022 | -1.34 Bn |
| Sep 30, 2022 | -1.28 Bn |
| Jun 30, 2022 | -270,000.00 |
| Mar 31, 2022 | -272,000.00 |
| Dec 31, 2021 | -1.05 Bn |
| Sep 30, 2021 | -1.00 Bn |
| Jun 30, 2021 | -267,000.00 |